// App-Quantinova.ai

10526 : Clinical, biologic, and outcome differences according to MIBG avidity in children with neuroblastoma: A report from the Childrens Oncology Group (COG).

Researchers

Presenter

  • Steven G. DuBois

Principal Investigators

  • Rajen Mody

  • Collin Van Ryn

  • Arlene Naranjo

  • Susan G. Kreissman

  • David Baker

  • Marguerite T Parisi

  • Barry L. Shulkin

  • John M. Maris

  • Vandana Batra

  • Julie R. Park

  • Katherine K. Matthay

  • Gregory A Yanik

Medical Centers

  • Dana-Farber Cancer Institute/Boston Children's Cancer and Blood Disorder Center, Boston, MA

  • University of Michigan, Ann Arbor, MI

  • University of Florida, Cainsvillle, FL

  • Children's Oncology Group Statistics and Data Center, University of Florida, Gainesville, FL

  • Duke University Medical Center, Durham, NC

  • Princess Margaret Hospital for Children, Perth, Australia

  • Seattle Childrens Hospital, Seattle, WA

  • St. Jude Children's Research Hospital, Memphis, TN

  • Childrens Hospital of Philadelphia, Philadelphia, PA

  • Childrens Hospital of Philadelphia, Philadelphia, PA

  • Seattle Children's Hospital and University of Washington School of Medicine, Seattle, WA

  • UC San Francisco, San Francisco, CA

  • University of Michigan Medical School, Ann Arbor, MI

Locations

  • United States

  • Australia

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Bone metastases

  • Neuroblastoma

Biomarkers

  • N/A

Drug/Treatment

  • MIBG

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved